| Asthma
Alvesco vs Dulera
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Alvesco vs Dulera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDulera has a higher rate of injection site reactions vs Alvesco based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dulera but not Alvesco, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvesco
Dulera
At A Glance
Oral inhalation
Twice daily
Inhaled corticosteroid
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Asthma
- Asthma
Dosing
Asthma 80 mcg twice daily by oral inhalation as starting dose for patients on bronchodilators alone or inhaled corticosteroids, up to 320 mcg twice daily; patients previously on oral corticosteroids start at 320 mcg twice daily (maximum).
Asthma (>=12 years) 2 inhalations twice daily of DULERA 100 mcg/5 mcg or 200 mcg/5 mcg via oral inhalation; maximum 2 inhalations of 200 mcg/5 mcg twice daily (800 mcg/20 mcg per day).
Asthma (5 to <12 years) 2 inhalations of DULERA 50 mcg/5 mcg twice daily via oral inhalation; maximum daily dose 200 mcg/20 mcg.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Known hypersensitivity to ciclesonide or any ingredient of ALVESCO
- Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures
- Known hypersensitivity to mometasone furoate, formoterol fumarate, or any ingredient in DULERA
Adverse Reactions
Most common (>=3%) Headache, nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, arthralgia, nasal congestion, pain in extremity, back pain
Serious Oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism, adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma, cataracts
Postmarketing Immediate or delayed hypersensitivity reactions including angioedema with swelling of lips, tongue, and pharynx
Most common (>=3%) Nasopharyngitis, sinusitis, headache; dysphonia reported at 4-5% in long-term (52-week) treatment; influenza, upper respiratory tract infection in pediatric patients aged 5 to <12 years.
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, growth effects in pediatrics, glaucoma and cataracts.
Postmarketing Angina pectoris, cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), vision blurred, anaphylactic reaction, angioedema, severe hypotension, rash, pruritus, QT prolongation, blood pressure increased, hypokalemia, hyperglycemia, asthma aggravation (cough, dyspnea, wheezing, bronchospasm).
Pharmacology
Ciclesonide is an inhaled corticosteroid prodrug hydrolyzed by esterases to its active metabolite des-ciclesonide, which binds glucocorticoid receptors with 120-fold greater affinity than the parent compound and exerts broad anti-inflammatory activity against mast cells, eosinophils, lymphocytes, macrophages, and neutrophils involved in the asthmatic response.
DULERA combines mometasone furoate, a synthetic corticosteroid with potent anti-inflammatory activity that inhibits multiple cell types and inflammatory mediators involved in the asthmatic response, and formoterol fumarate, a selective long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase and inhibiting mast cell mediator release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvesco
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Dulera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Alvesco
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (3/8)
Dulera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Alvesco
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (3/3)
Dulera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alvesco.
No savings programs available for Dulera.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvescoView full Alvesco profile
DuleraView full Dulera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.